Swallowing DisordersNCT04770441
Transoral Incisionless Fundoplication in Post-POEM GERD
An observational study of Swallowing Disorders and Achalasia, run by Baylor College of Medicine at 1 site in United States.
Trial summary
POEM (per oral endoscopic myotomy) is effective for the treatment of swallowing disorders but can induce acid reflux. If acid reflux remains untreated in this situation, it can lead to significant problems. Thus, minimizing abnormal acid exposure after POEM is very important. Read more about this study
- Who is it for?
- Ages 18 to 64 years
- Conditions the study is for
- Swallowing Disorders, Achalasia, Outlet Obstruction, Gastric
- How many people
- 7 participants
- Where
- 1 siteUnited States
- Study dates
- 17 Mar 2021to 3 Jun 2023
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- No healthy volunteers
- Adult
Study population: Patients with confirmed indications for POEM (achalasia, jackhammer esophagus, EGJOO, diffuse esophageal spasm) will be identified as potential study patients. These patients will undergo objective testing and will be required to complete subjective questionnaires for achalasia and GERD as part of the standard work up (off of PPI therapy). Additionally, chart review of their medical records will be conducted for clinical outcomes. These include: - pre-POEM esophageal manometry and pH testing - GERD-HRQL (separate heartburn and regurgitation scores) - Eckardt scores - EGD pre-POEM (patients will be assessed for hiatal hernia as documented by length, diameter, and Hill grade)
Who may be able to join
- Age greater than 18 years old
- Able to sign consent
- Patients must meet standard clinical indications for POEM procedure (all indications) for the initial enrollment
- To undergo TIF: Evidence of GERD/GERD related complications after POEM:
- pathologic acid exposure on pH testing (Deemester score >14.72 or percentage time pH <4 greater than 5.3%) off of PPI (19)
- esophagitis on EGD (grades A to C)
- biopsies showing evidence of reflux esophagitis
Who cannot join
- Adults unable to consent
- Pregnant women - Prisoners
- Delayed gastric emptying
- Code status of DNR/DNI or CMO
- Any patient with moderate to severe esophagitis pre-POEM
- Grade D esophagitis post POEM
Show all 13Show fewer
- Hiatal hernia >2cm
- PPI use prior to POEM (and if PPI is needed)
- Previous surgery of the stomach
- Known GI malignancy
- Cirrhosis with portal hypertension, varices, or ascites
- Previous anti-reflux surgery
- Patients who choose not to undergo TIF or if insurance will not cover the procedure.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Evaluation of the Use of TIF (Transoral Incisionless Fundoplication) to Treat Post-poem GERD
POEM (per oral endoscopic myotomy) is effective for the treatment of swallowing disorders but can induce acid reflux. If acid reflux remains untreated in this situation, it can lead to significant problems. Thus, minimizing abnormal acid exposure after POEM is very important. Typically, this is done with acid suppression medications such as Prilosec or Nexium. However, long term acid suppression medication has been linked to possible long-term complications. Transoral incisionless fundoplication (TIF) has been approved for the treatment of reflux, but its use in reflux after POEM has not been investigated in detail. We hypothesize TIF will be able to decrease the amount of acid reflux in to the esophagus, thereby allowing patients to remain off of acid suppression medications.
Once enrolled into the study, you will undergo the POEM procedure. 3 months after the procedure we will assess for abnormal reflux via questionnaires and diagnostic testing as part of the standard management post POEM. If there is evidence of abnormal reflux, the TIF procedure will be performed. 3 months after the TIF, you will have similar testing again to document resolution in abnormal acid reflux.You will be followed for 12 months as part of the study. If at the 3 month mark, there is no evidence of abnormal reflux, you will neither be placed on PPI nor undergo TIF and will be followed for 12 months to assess for abnormal reflux
Read the detailed description
EGD (esophagogastroduodenoscopy) is a safe procedure used extensively to evaluate the esophagus, stomach and small intestine. With the assistance of the anesthesiology team, we will put you to sleep partially to minimize discomfort during the insertion of the endoscopy. This is normally how this procedure is performed and deemed very safe. Potential complications include breathing problems, holes in the intestine, and bleeding. These occur very infrequently. In our study, EGD will be used at three checkpoints (all of which are part of standard of care):
- at the time of POEM to rule out other unusual structural abnormalities
- at 3 months during measurement of acid exposure in the esophagus via Bravo pH
- 3 months after TIF placement (6 months after enrollment and POEM) to document resolution in acid reflux.
Esophageal manometry is a non-endoscopic procedure that involves using a safe numbing cream to allow passage of the manometry catheter from the nose down to the end of the esophagus. Different measurements are taken from the catheter and the catheter is then removed. This is a standard of care procedure in the evaluation of patients with esophageal motility/swallowing disorders. It will be used in the following settings and all are part of standard of care:
- 3 months after POEM as part of standard of care to assess improvement in the swallowing
- 3 months after TIF (6 months post POEM) only if swallowing issues reappear.
Bravo pH study is used to assess abnormal acid reflux and is considered gold standard in identifying the degree of acid reflux. It is standard of care for this procedure to be performed in patients with suspected acid reflux and post-POEM to assess need for long term acid suppression. It involves performing an endoscopy first, followed by deployment and implantation of the Bravo pH capsule into the end of the esophagus. Risks include bleeding, injury to the esophagus or dislodgment of the capsule. However, these are rare instances.
POEM Those enrolled into the study will undergo a diagnostic endoscopy at the same allotted time as the POEM. It will be explained to you in detail but involves endoscopically cutting the muscle at the end of the esophagus, called a myotomy. It is less invasive than its surgical equivalent Heller's myotomy, but equally effective. Two endoscopist (one with extensive experience in POEM and the other with formal training in POEM) will be performing the actual POEM procedures.
TIF The TIF procedure is performed using the FDA approved EsophyX-Z device (EndoGastricSolutions, Redmond, Wash, USA). It has been shown to be effective in the management of acid reflux in patients who fail acid suppression therapy or in patients who would like to avoid long term acid suppression with acid suppression therapy due to the potential side effects. It involves the use of a flexible suturing apparatus that fits over the endoscope and is used to create an artificial wrap around the end of the esophagus, thereby mimicking the effects of the typical surgical wrap. In the right setting it is as effective as its surgical counterpart but less invasive. Due to the incisionless approach, patients undergoing TIF experience less discomfort and faster recovery than those undergoing traditional anti-reflux surgery.
- Keywords
- Per-Oral Endoscopic Myotomy (POEM), Submucosal Endoscopy
- Medical subject headings
- Deglutition Disorders, Esophageal Achalasia, Gastric Outlet Obstruction, Esophageal Spasm, Diffuse
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of patients not requiring PPI therapy at set endpoints
If at least 50% of patients do not require initiation of PPI therapy at the end of the study, then TIF would be considered successful.
Measured: 1 year
Secondary outcomes (5)
At least 50% of patients with a 50% decrease in GERD-HQRL 3 months post TIF (20)
Assessed and evaluated at protocol's scheduled visits.
Measured: 1 year
Decrease in Demeester scores to less than 14.72 (above this number is consider pathologic acid reflux) in at least 50% of patients
Assessed and evaluated at protocol's scheduled visits.
Measured: 1 year
50% decrease in the number of patients with percentage of time of acid exposure (pH <4) was less than or equal to 5.3%
Assessed and evaluated at protocol's scheduled visits.
Measured: 1 year
50% decrease in the number of patients with percentage time pH <4 reduced to 30% of the pre-TIF value (21)
Assessed and evaluated at protocol's scheduled visits.
Measured: 1 year
50% improvement in esophageal GERD related
Assessed and evaluated at protocol's scheduled visits.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2021
- Study start17 Mar 2021
- Primary completion15 Oct 2022
- Study completion3 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Swallowing DisordersStudies of the same condition, open and under way.
- More trials run by Baylor College of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 7 participants (actual)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Baylor College of Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Salmaan Azam Jawaid, MD, Baylor College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04770441
- Sponsor's protocol ID
- H-48496
- Status last verified
- Aug 2023
- First submitted
- 22 Feb 2021
- Last updated
- 18 Aug 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is a single-site prospective study.
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Evaluation of the Use of TIF (Transoral Incisionless Fundoplication) to Treat Post-poem GERD
- ClinicalTrials.gov ID
- NCT04770441
- Acronym / sponsor ID
- H-48496
- Keywords
- Per-Oral Endoscopic Myotomy (POEM), Submucosal Endoscopy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 7 participants (actual)
- Lead sponsor
- Baylor College of MedicineUniversity, hospital or other
- Study start
- 17 Mar 2021 (actual)
- Primary completion
- 15 Oct 2022 (actual)
- Study completion
- 3 Jun 2023 (actual)
- First posted
- 25 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
POEM (per oral endoscopic myotomy) is effective for the treatment of swallowing disorders but can induce acid reflux. If acid reflux remains untreated in this situation, it can lead to significant problems. Thus, minimizing abnormal acid exposure after POEM is very important. Typically, this is done with acid suppression medications such as Prilosec or Nexium. However, long term acid suppression medication has been linked to possible long-term complications. Transoral incisionless fundoplication (TIF) has been approved for the treatment of reflux, but its use in reflux after POEM has not been investigated in detail. We hypothesize TIF will be able to decrease the amount of acid reflux in to the esophagus, thereby allowing patients to remain off of acid suppression medications.
Once enrolled into the study, you will undergo the POEM procedure. 3 months after the procedure we will assess for abnormal reflux via questionnaires and diagnostic testing as part of the standard management post POEM. If there is evidence of abnormal reflux, the TIF procedure will be performed. 3 months after the TIF, you will have similar testing again to document resolution in abnormal acid reflux.You will be followed for 12 months as part of the study. If at the 3 month mark, there is no evidence of abnormal reflux, you will neither be placed on PPI nor undergo TIF and will be followed for 12 months to assess for abnormal reflux
Detailed description
EGD (esophagogastroduodenoscopy) is a safe procedure used extensively to evaluate the esophagus, stomach and small intestine. With the assistance of the anesthesiology team, we will put you to sleep partially to minimize discomfort during the insertion of the endoscopy. This is normally how this procedure is performed and deemed very safe. Potential complications include breathing problems, holes in the intestine, and bleeding. These occur very infrequently. In our study, EGD will be used at three checkpoints (all of which are part of standard of care):
- at the time of POEM to rule out other unusual structural abnormalities
- at 3 months during measurement of acid exposure in the esophagus via Bravo pH
- 3 months after TIF placement (6 months after enrollment and POEM) to document resolution in acid reflux.
Esophageal manometry is a non-endoscopic procedure that involves using a safe numbing cream to allow passage of the manometry catheter from the nose down to the end of the esophagus. Different measurements are taken from the catheter and the catheter is then removed. This is a standard of care procedure in the evaluation of patients with esophageal motility/swallowing disorders. It will be used in the following settings and all are part of standard of care:
- 3 months after POEM as part of standard of care to assess improvement in the swallowing
- 3 months after TIF (6 months post POEM) only if swallowing issues reappear.
Bravo pH study is used to assess abnormal acid reflux and is considered gold standard in identifying the degree of acid reflux. It is standard of care for this procedure to be performed in patients with suspected acid reflux and post-POEM to assess need for long term acid suppression. It involves performing an endoscopy first, followed by deployment and implantation of the Bravo pH capsule into the end of the esophagus. Risks include bleeding, injury to the esophagus or dislodgment of the capsule. However, these are rare instances.
POEM Those enrolled into the study will undergo a diagnostic endoscopy at the same allotted time as the POEM. It will be explained to you in detail but involves endoscopically cutting the muscle at the end of the esophagus, called a myotomy. It is less invasive than its surgical equivalent Heller's myotomy, but equally effective. Two endoscopist (one with extensive experience in POEM and the other with formal training in POEM) will be performing the actual POEM procedures.
TIF The TIF procedure is performed using the FDA approved EsophyX-Z device (EndoGastricSolutions, Redmond, Wash, USA). It has been shown to be effective in the management of acid reflux in patients who fail acid suppression therapy or in patients who would like to avoid long term acid suppression with acid suppression therapy due to the potential side effects. It involves the use of a flexible suturing apparatus that fits over the endoscope and is used to create an artificial wrap around the end of the esophagus, thereby mimicking the effects of the typical surgical wrap. In the right setting it is as effective as its surgical counterpart but less invasive. Due to the incisionless approach, patients undergoing TIF experience less discomfort and faster recovery than those undergoing traditional anti-reflux surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Patients with confirmed indications for POEM (achalasia, jackhammer esophagus, EGJOO, diffuse esophageal spasm) will be identified as potential study patients. These patients will undergo objective testing and will be required to complete subjective questionnaires for achalasia and GERD as part of the standard work up (off of PPI therapy). Additionally, chart review of their medical records will be conducted for clinical outcomes. These include: - pre-POEM esophageal manometry and pH testing - GERD-HRQL (separate heartburn and regurgitation scores) - Eckardt scores - EGD pre-POEM (patients will be assessed for hiatal hernia as documented by length, diameter, and Hill grade)
Key inclusion criteria (7 listed)
- Age greater than 18 years old
- Able to sign consent
- Patients must meet standard clinical indications for POEM procedure (all indications) for the initial enrollment
- To undergo TIF: Evidence of GERD/GERD related complications after POEM:
- pathologic acid exposure on pH testing (Deemester score >14.72 or percentage time pH <4 greater than 5.3%) off of PPI (19)
Key exclusion criteria (13 listed)
- Adults unable to consent
- Pregnant women - Prisoners
- Delayed gastric emptying
- Code status of DNR/DNI or CMO
- Any patient with moderate to severe esophagitis pre-POEM
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of patients not requiring PPI therapy at set endpoints
Time frame: 1 year
If at least 50% of patients do not require initiation of PPI therapy at the end of the study, then TIF would be considered successful.
5 secondary outcomes
At least 50% of patients with a 50% decrease in GERD-HQRL 3 months post TIF (20)
Time frame: 1 year
Decrease in Demeester scores to less than 14.72 (above this number is consider pathologic acid reflux) in at least 50% of patients
Time frame: 1 year
50% decrease in the number of patients with percentage of time of acid exposure (pH <4) was less than or equal to 5.3%
Time frame: 1 year
50% decrease in the number of patients with percentage time pH <4 reduced to 30% of the pre-TIF value (21)
Time frame: 1 year
50% improvement in esophageal GERD related
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2023.
- Individual participant dataSharing planned: No. This is a single-site prospective study.
Related trials for Swallowing Disorders
Recruiting
taVNS in Infants Severe Dysphagia
Dysphagia, Swallowing Disorders
Not yet recruitingPhase 2
Early Feeding TL Trial
Total Laryngectomy
Recruiting
The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
Dysphagia, Eosinophilic Esophagitis
Active, not recruitingObservational study
RETHINK REFLUX Registry
Gastroesophageal Reflux
Recruiting
Evaluation of the Impact of Periodontitis and Its Treatment on Swallowing Functions and Oral Quality of Life
Periodontitis, Periodontal Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Swallowing Disorders and Achalasia, run by Baylor College of Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of patients not requiring PPI therapy at set endpoints (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2023.